ArticleEndocrine, metabolic & immune disorders drug targets2026
Gamma-Glutamyl Transferase and Male Reproductive Hormone Levels in Men with Type 2 Diabetes: A Cross-Sectional Study
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough Gamma-Glutamyl Transferase (GGT) has been implicated in metabolic disorders, its association with male reproductive hormones in type 2 diabetes mellitus (T2DM) remains unclear.
methodsIn this cross-sectional study, 971 men with T2DM were recruited from Shandong Provincial Hospital. Serum GGT levels were measured as the primary exposure variable, while male reproductive hormones—including total testosterone (TT), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and sex hormone-binding globulin (SHBG)—served as outcome variables. Multivariable linear regression, threshold effect models, and subgroup analyses were used to assess associations, adjusting for age, BMI, glycemic control, and other confounders.
resultsThe mean age of participants was 56.37 ± 12.49 years. After full adjustment, men in the highest GGT tertile exhibited a 0.44 ng/mL reduction in TT levels compared to the lowest tertile (p < 0.01). A nonlinear relationship was identified, with a saturation effect at GGT = 118 IU/L. Below this threshold, each 10-IU/L increase in GGT corresponded to a 0.13 ng/mL decrease in TT (95% CI: -0.21 to -0.05). Unadjusted inverse associations with SHBG (β = -14.87, 95% CI: -26.47 to -3.28) and LH (β = -1.34, 95% CI: -2.14 to -0.54) became nonsignificant after adjustment (p>0.05). No FSH associations were detected. DISCUSSION: Our findings reveal a novel dose-dependent relationship between GGT and TT in T2DM, with effects plateauing beyond 118 IU/L. This threshold may reflect the point where oxidative stress overwhelms gonadal compensatory mechanisms.
conclusionThe nonlinear relationship between GGT and TT suggests GGT may help identify androgen deficiency risk in T2DM though SHBG/LH links appear confounder-dependent. Monitoring GGT could aid T2DM male health management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.